Selection of an immunogenic and protective epitope of the PsaA protein of Streptococcus pneumoniae using a phage display library

Hybridoma

Volumn 19, Issue 1, 2000, Pages 23-31

  Srivastava, N ^a   Zeiler, J L ^a   Smithson, S L ^a   Carlone, G M ^b   Ades, E W ^b   Sampson, J S ^b   Johnson, S E ^b   Kieber Emmons, T ^c   Westerink, M A J ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; EPITOPE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; POLYSACCHARIDE VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL CELL WALL; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; CONTROLLED STUDY; GENE MAPPING; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STREPTOCOCCUS PNEUMONIAE;

ADHESINS, BACTERIAL; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CARRIER PROTEINS; IMMUNODOMINANT EPITOPES; LIPOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PHAGES; STREPTOCOCCUS PNEUMONIAE;

ANIMALIA; BACTERIA (MICROORGANISMS); POSIBACTERIA; STREPTOCOCCUS PNEUMONIAE; UNIDENTIFIED BACTERIOPHAGE;

EID: 0034070094     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/027245700315761     Document Type: Article

References (64)

1. Robbins JB, Austrian R, Lee CJ, et al.: Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983;148:1136-1159.
2. Wenger JD, Hightower AW, Facklam RR, Gaventa S, and Broome CV: Bacterial meningitis in the United States, 1986: Report of a multistate surveillance study. The Bacterial Meningitis Study Group. J Infect Dis 1990;162:1316-1323.
3. Breiman RF, Spika JS, Navarro VJ, Darden PM, and Darby CP: Pneumococcal bacteremia in Charleston county, South Carolina. A decade later. Arch Intern Med 1990;150:1401-1405.
4. Istre GR, Tarpay M, Anderson M, Pryor A, and Welch D: Invasive disease due to Streptococcus pneumoniae in an area with a high rate of relative penicillin resistance. J Infect Dis 1987;156:732-735.
5. Austrian R: The pneumococcus at the millennium: not down, not out. J Infect Dis 1999;179:S338-S341.
6. Stansfield SK: Acute respiratory infections in the developing world: Strategies for prevention, treatment and control. Pediatr Infect Dis J 1987;6:622-629.
7. de Louvois J, Blackbourn J, Hurley R, and Harvey D: Infantile meningitis in England and Wales: A two year study. Arch Dis Child 1991;66:603-607.
8. Bluestone CD, Stephenson JS, and Martin LM: Ten-year review of otitis media pathogens. Pediatr Infect Dis J 1992;11:S7-11.
9. Schappert SM: Vital and Health Statistics of the CDC, vol. 214. National Center for Health Statistics, Atlanta, 1992.
10. Afessa B, Greaves WL, and Frederick WR: Pneumococcal bacteremia in adults: A 14-year experience in an inner-city university hospital. Clin Infect Dis 1995;21:345-351.
11. Hook EWd, Horton CA, and Schaberg DR: Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983;249:1055-1057.
12. Kramer MR, Rudensky B, Hadas-Halperin I, Isacsohn M, and Melzer E: Pneumococcal bacteremia - no change in mortality in 30 years: Analysis of 104 cases and review of the literature. Isr J Med Sci 1987;23:174-180.
13. MacLeod CM, Hodges RG, Heidelberger M, and Bernhard WG: Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945;82:445-465.
14. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, and Facklam RR: Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270: 1826-1831.
15. Shapiro ED, Berg AT, Austrian R, et al.: The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New Engl J Med 1991;325:1453-1460.
16. van Dam JE, Fleer A, and Snippe H: Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides. Antonie Van Leeuwenhoek 1990;58:1-47.
17. Janoff EN, O'Brien J, Thompson P, et al.: Streptococcus pneumoniae colonization, bacteremia, and immune response among persons with human immunodeficiency virus infections. J Infect Dis 1993;167:49-56.
18. Daum RS, Hogerman D, Rennels MB, et al.: Infant immunization with pneumococcal CRM197 vaccines: Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J Infect Dis 1997;176:445-455.
19. Ahman H, Kayhty H, Tamminen P, Vuorela A, Malinoski F, and Eskola J: Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J 1996;15:134-139.
20. Leach A, Ceesay SJ, Banya WA, and Greenwood BM: Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J 1996;15:333-339.
21. Chan CY, Molrine DC, George S, et al.: Pneumococcal conjugate vaccine primes for antibody responses to pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996;173:256-258.
22. Butler JC, Breiman RF, Lipman HB, Hofmann J, and Facklam RR: Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis 1995;171:885-889.
23. Shapiro ED, and Austrian R: Serotypes responsible for invasive Streptococcus pneumoniae infections among children in Connecticut. J Infect Dis 1994;169:212-214.
24. Sniadack DH, Schwartz B, Lipman H, et al.: Potential interventions for the prevention of childhood pneumonia: Geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children - implications for vaccine strategies. Pediatr Infect Dis J 1995;14:503-510.
25. Dagan R: Epidemiology of pediatric meningitis caused by Haemophilus influenzae B, Streptococcus pneumoniae and Neisseria meningitidis in Israel. Isr J Med Sci 1994;30:351-355.
26. Jette LP, and Lamothe F: Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: Serotype distribution, antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol 1989;27:1-5.
27. Powers DC, Anderson EL, Lottenbach K, and Mink CM: Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996;173:1014-1018.
28. Storek J, Mendelman PM, Witherspoon RP, McGregor BA, and Storb R: IgG response to pneumococcal polysaccharide-protein conjugate appears similar to IgG response to polysaccharide in bone marrow transplant recipients and healthy adults. Clin Infect Dis 1997;25:1253-1255.
29. Molrine DC, George S, Tarbell N, et al.: Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Ann Intern Med 1995;123:828-834.
30. Ahmed F, Steinhoff MC, Rodriquez-Barradas MC, Hamilton RG, Musher DM, and Nelson KE: Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: Results from a randomized trial. J Infect Dis 1996;173:83-90.
31. Seppala I, Pelkonen J, and Makela O: Isotypes of antibodies induced by plain dextran or a dextran-protein conjugate. Eur J Immunol 1985;15:827-833.
32. Seppala I, Sarvas H, Makela O, Mattila P, Eskola J, and Kayhty H: Human antibody responses to two conjugate vaccines of Haemophilus influenzae type B saccharides and diphtheria toxin. Scand J Immunol 1988;28:471-479.
33. Peeters CC, Tenbergen-Meekes AM, Pooman JT, Beurret M, Zegers BJ, and Rijkers GT: Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun 1991;59:3504-3510.
34. Russell H, Tharpe JA, Wells DE, White EH, and Johnson JE: Monoclonal antibody recognizing a species-specific protein from Streptococcus pneumoniae. J Clin Microbiol 1990;28:2191-2195.
35. Sampson JS, Furlow Z, Whitney AM, Williams D, Facklam R, and Carlone GM: Limited diversity of Streptococcus pneumoniae psaA among pneumococcal vaccine serotypes. Infect Immun 1997;65:1967-1971.
36. Berry AM, and Paton JC: Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect Immun 1996;64:5255-5262.
37. Lawrence MC, Pilling PA, Epa VC, Berry AM, Ogunniyi AD, and Paton JC: The crystal structure of pneumococcal surface antigen PsaA reveals a metal-binding site and a novel structure for a putative ABC-type binding protein. Structure 1998;6:1553-1561.
38. Dintilhac A, Alloing G, Granadel C, and Claverys JP: Competence and virulence of Streptococcus pneumoniae: Adc and PsaA mutants exhibit a requirement for Zn and Mn resulting from inactivation of putative ABC metal permeases. Mol Microbiol 1997;25:727-739.
39. Crook J, Tharpe JA, Johnson SE, et al.: Immunoreactivity of five monoclonal antibodies against the 37-kilodalton common cell wall protein (PsaA) of Streptococcus pneumoniae. Clin Diagn Lab Immunol 1998;5:205-210.
40. Tharpe JA, and Russell H: Purification and seroreactivity of pneumococcal surface adhesin A (PsaA). Clin Diagn Lab Immunol 1996;3:227-229.
41. Talkington DF, Brown BG, Tharpe JA, Koenig A, and Russell H: Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb Pathog 1996;21:17-22.
42. Parmley SF, and Smith GP: Antibody-selectable filamentous fd phage vectors: Affinity purification of target genes. Gene 1988;73:305-318.
43. Scott JK, and Smith GP: Searching for peptide ligands with an epitope library. Science 1990;249:386-390.
44. Smith GP, and Scott JK: Libraries of peptides and protein displayed on filamentous phage. Methods Enzymol 1993;217:228-257.
45. Lowell GH, Ballou WR, Smith LF, Wirtz RA, Zollinger WD, and Hockmeyer WT: Proteosome-lipopeptide vaccines: Enhancement of immunogenicity for Malaria CS peptides. Science 1988;240:800-802.
46. Lowell GH, Smith LF, Seid RC, and Zollinger WD: Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants. J Exp Med 1988;167:658-663.
47. Lowell GH: Proteosomes, hydrophobic anchors, iscoms, and liposomes for improved presentation of peptide and protein vaccines. In: New Generation Vaccines. Woodrow GM, Levine MM (Ed.). Marcel Dekker, Inc., New York, 1990, pp. 141-160.
48. Zollinger WD, Mandrell RE, Griffiss JM, Altieri P, and Berman S: Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogens in man. J Clin Invest 1979;63:836-848.
49. Wu HY, Virolainen A, Mathews B, King J, Russell MW, and Briles DE: Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathog 1997;23:127-137.
50. Rijkers GT, and Mosier DE: Pneumococcal polysaccharides induce antibody formation by human B lymphocytes in vitro. J Immunol 1985;135:1-4.
51. Douglas RM, Paton JC, Duncan SJ, and Hansman DJ: Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983;148:131-137.
52. Douglas RM, and Miles HB: Vaccination against Streptococcus pneumoniae in childhood: Lack of demonstrable benefit in young Australian children. J Infect Dis 1984;149:861-869.
53. Bottger V, Stasiak PC, Harrison DL, Mellerick DM, and Lane EB: Epitope mapping of monoclonal antibodies to keratin 19 using keratin fragments, synthetic peptides and phage peptide libraries. Eur J Biochem 1995;231:475-485.
54. Hoess R, Brinkmann U, Handel T, and Pastan I: Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene 1993;128:43-49.
55. Valadon P, Nussbaum G, Oh J, and Scharff MD: Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide. J Immunol 1998;161:1829-1836.
56. Oldenburg KR, Loganathan D, Goldstein IJ, Schultz PG, and Gallop MA: Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc Natl Acad Sci USA 1992;89:5393-5397.
57. Westerink MAJ, Giardina PC, Apicella MA, and Kieber-Emmons T: Peptide mimicry of the meningococcal group C capsular polysaccharide. Proc Natl Acad Sci USA 1995;92:4021-4025.
58. MacKenzie R, and To R: The role of valency in the selection of anti-carbohydrate single-chain Fvs from phage display libraries. J Immunol Methods 1998;220:39-49.
59. Chirinos-Rojas CL, Steward MW, and Partidos CD: A peptidomimetic antagonist of TNF-alpha-mediated cytotoxicity identified from a phage-displayed random peptide library. J Immunol 1998;161:5621-5626.
60. Zhong G, Berry JD, and Choukri S: Mapping epitopes of neutralizing monoclonal antibodies using phage random peptide libraries. J Ind Microbiol Biotechnol 1997;19:71-76.
61. Grothaus M, Srivastava N, Smithson SL, and Westerink MAJ: Selection of a peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine 2000:18;1253-1263.
62. da Fonseca DP, Joosten D, van der Zee R, et al.: Identification of new cytotoxic T-cell epitopes on the 38-kilodalton lipoglycoprotein of Mycobacterium tuberculosis by using lipopeptides. Infect Immun 1998;66:3190-3197.
63. + cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants [In Process Citation]. Vaccine 1999;17:2974-2982 [MEDLINE record in process].
64. Moore A, McCarthy L, and Mills KH: The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 1999;17:2517-2527